Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study
Completed
Abbott
N/A
2002-08-01
The primary study hypothesis of this study is to determine whether there is a greater
percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of
simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or
fenofibrate 160mg monotherapy.
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study
Completed
Merck Sharp & Dohme Corp.
N/A
2002-08-01
The primary study hypothesis of this study is to determine whether there is a greater
percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of
simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or
fenofibrate 160mg monotherapy.
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study
Completed
Intermountain Health Care, Inc.
N/A
2002-08-01
The primary study hypothesis of this study is to determine whether there is a greater
percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of
simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or
fenofibrate 160mg monotherapy.
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
Completed
Aegerion Pharmaceuticals, Inc.
Phase 2
2006-03-01
This phase II, open-label research study was conducted in 129 healthy volunteers. Each
subject will be given one initial oral dose of one of 7 FDA-approved medications (probe
drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10
or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug
that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return
in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10)
or fifteen (15) subjects.
Safety, pharmacokinetic and pharmacodynamic assessments will be performed.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
